2nd Neuroscience Innovation Partnering and Licensing Summit

From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.

 

Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering and Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting.

 

Who Attends This Differentiated Business Development Initiative

 

- Global Pharma: Heads of Business Development, Search and Evaluation, and Asset Scouting for Neuroscience - comparing pipelines and enabling technologies to fuel future innovation.

- Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain - seeking feedback, validation, and strategic partnerships with pharma and investors.

- Investors and Venture Capital: Leaders focused on neuroscience investments with higher risk appetite - looking for insights into pharma strategy and access to breakthrough opportunities.

 

Less competitive and more accessible, pharma can assess related programs back-to-back, while biotech has a protected opportunity to meet multiple big pharma players against the backdrop of market intelligence.